---
title: "Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290979037.md"
description: "Capricor Therapeutics (CAPR) shares fell approximately 12% after the FDA scheduled an advisory committee meeting for July 29 to review its Biologics License Application for Deramiocel, a Duchenne muscular dystrophy treatment. This follows a previous rejection in July 2025 and a resubmitted application accepted in March with a target action date of August 22."
datetime: "2026-06-26T14:15:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290979037.md)
  - [en](https://longbridge.com/en/news/290979037.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290979037.md)
generator: "portal-rs"
---

# Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy


### Related Stocks

- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)

## Related News & Research

- [CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit](https://longbridge.com/en/news/298416418.md)
- [Bank of New York Mellon Corp Acquires Shares of 161,767 Capricor Therapeutics, Inc. $CAPR](https://longbridge.com/en/news/298126167.md)
- [13:45 ETCapricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/298064159.md)
- [SLDB: Pivotal gene therapy data and regulatory milestones for DMD and FA expected in early 2025](https://longbridge.com/en/news/298506641.md)
- [16:54 ETCAPR Stock Alert: Capricor Therapeutics, Inc. Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman](https://longbridge.com/en/news/297958306.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**